Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP.
Document Type
Article
Publication Date
2000
Keywords
Blotting-Southern, Blotting-Western, Bone-Marrow-Cells, Cell-Transplantation, Genes-Suppressor-Tumor, Hematologic-Neoplasms, Hematopoiesis, Heterozygote, Loss-of-Heterozygosity, Mice, Mice-Inbred-C57BL, Mice-Knockout, Nuclear-Proteins, Phenotype, Spleen, SUPPORT-NON-U-S-GOVT, SUPPORT-U-S-GOVT-P-H-S, Trans-Activators
First Page
272
Last Page
277
JAX Source
Genes Dev 2000 Feb; 14(3):272-7.
Abstract
Mice with monoallelic inactivation of the CBP gene develop highly penetrant, multilineage defects in hematopoietic differentiation and, with advancing age, an increased incidence of hematologic malignancies. The latter are characterized, at least in some cases, by loss of heterozygosity (LOH) at the CBP locus. No such pathology was observed in wild-type or p300 heterozygous null mice of the same age and genetic background. Thus, a full complement of CBP, but not p300, is required for normal hematopoietic differentiation. These results also provide the first experimental evidence for the hypothesis that CBP has tumor-suppressing activity.
Recommended Citation
Kung AL,
Rebel VI,
Bronson RT,
Ch'ng LE,
Sieff CA,
Livingston DM,
Yao TP.
Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. Genes Dev 2000 Feb; 14(3):272-7.